inactivated poliovirus type 2
PolandDrugs containing this active substance
-
The vaccine is used to strengthen protection against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It is used in children from 3 years of age, adolescents, and adults after a full course of primary vaccinations.
Form: solution for injection in ampoule-syringe
Active substance Dosage diphtheria toxoid Not less than 2 IU (2 Lf) tetanus toxoid Not less than 20 IU (5 Lf) pertussis toxoid 2.5 mcg fibrillar hemagglutinin 5 mcg pertactin 3 mcg fimbriae (type 2 and 3) 5 mcg inactivated poliovirus type 1 29 units of D3 antigen inactivated poliovirus type 2 7 units of D3 antigen inactivated poliovirus type 3 26 units of D3 antigen ATC: J07CA02
Manufacturer: Sanofi-Aventis Zrt.
-
The vaccine is used to prevent diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It helps the body develop immunity to these four diseases.
Form: solution for injection in ampoule-syringe
Active substance Dosage diphtheria toxoid > or equal to 2 IU (2.5 Lf) aluminum phosphate 0.2 mg Al 3+ inactivated poliovirus type 1 40 units of antigen D inactivated poliovirus type 2 8 units of antigen D inactivated poliovirus type 3 32 units of antigen D tetanus toxoid > or equal 20 IU (5 Lf) aluminum hydroxide hydrate 0.3 mg Al 3+ bordetella pertussis antigens 8 mcg + 8 mcg + 2.5 mcg ATC: J07CA02
Manufacturer: GlaxoSmithKline Biologicals S.A.
-
The vaccine is used to prevent diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio).
Form: suspension for injection
Active substance Dosage inactivated poliovirus type 1 40 units of antigen D inactivated poliovirus type 2 8 units of antigen D inactivated poliovirus type 3 32 units of antigen D diphtheria toxoid or equal to 30 IU tetanus toxoid or equal to 40 IU pertussis antigens 25 mcg + 25 mcg + 8 mcg ATC: J07CA02
Manufacturer: GlaxoSmithKline Biologicals S.A.
-
The vaccine helps protect children from 6 weeks of age against diphtheria, tetanus, pertussis, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b (such as meningitis or septicaemia).
Form: powder and suspension for preparation of injection suspension
Active substance Dosage inactivated poliovirus type 1 40 units of antigen D inactivated poliovirus type 2 8 units of antigen D inactivated poliovirus type 3 32 units of antigen D haemophilus influenzae type b conjugated polysaccharide-tetanus toxoid conjugate 10 mcg diphtheria toxoid not less than 30 IU tetanus toxoid not less than 40 IU bordetella pertussis antigens 25 mcg + 25 mcg ATC: J07CA02
Manufacturer: Sanofi Winthrop Industrie